- Home
- PRA vs VRDN Comparison
PRA vs VRDN Comparison
Compare PRA & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRA
- VRDN
- Stock Information
- Founded
- PRA 1976
- VRDN 2006
- Country
- PRA United States
- VRDN United States
- Employees
- PRA N/A
- VRDN N/A
- Industry
- PRA Property-Casualty Insurers
- VRDN Medical Specialities
- Sector
- PRA Finance
- VRDN Health Care
- Exchange
- PRA Nasdaq
- VRDN Nasdaq
- Market Cap
- PRA 1.2B
- VRDN 1.3B
- IPO Year
- PRA N/A
- VRDN N/A
- Fundamental
- Price
- PRA $23.96
- VRDN $18.44
- Analyst Decision
- PRA Hold
- VRDN Strong Buy
- Analyst Count
- PRA 4
- VRDN 11
- Target Price
- PRA $21.00
- VRDN $38.80
- AVG Volume (30 Days)
- PRA 551.0K
- VRDN 733.6K
- Earning Date
- PRA 08-05-2025
- VRDN 08-06-2025
- Dividend Yield
- PRA N/A
- VRDN N/A
- EPS Growth
- PRA N/A
- VRDN N/A
- EPS
- PRA 0.95
- VRDN N/A
- Revenue
- PRA $1,128,928,000.00
- VRDN $305,000.00
- Revenue This Year
- PRA N/A
- VRDN N/A
- Revenue Next Year
- PRA $0.58
- VRDN $17,102.33
- P/E Ratio
- PRA $25.31
- VRDN N/A
- Revenue Growth
- PRA N/A
- VRDN 5.90
- 52 Week Low
- PRA $12.43
- VRDN $9.90
- 52 Week High
- PRA $24.14
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- PRA 65.85
- VRDN 61.44
- Support Level
- PRA $23.61
- VRDN $15.68
- Resistance Level
- PRA $24.14
- VRDN $19.10
- Average True Range (ATR)
- PRA 0.11
- VRDN 0.99
- MACD
- PRA -0.00
- VRDN 0.06
- Stochastic Oscillator
- PRA 65.09
- VRDN 80.70
About PRA ProAssurance Corporation
ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in five segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, Lloyd's Syndicate, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).